{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:50:05Z","timestamp":1768557005642,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/03"],"award-info":[{"award-number":["MC_UU_00004\/03"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare BMI\u2010for\u2010age <jats:italic>z<\/jats:italic>\u2010score (zBMI) changes in treatment\u2010experienced children and young people living with HIV aged 6 to &lt;25\u2009years on tenofovir alafenamide fumarate (TAF) to those on tenofovir disoproxil fumarate (TDF) and abacavir (ABC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cohort study of children and young people living with HIV from 12 European countries were grouped by drug exposure: 1 \u2010 on TAF with prior TDF use; 2 \u2010 on TAF no prior TDF; 3 \u2010 on TDF; and 4 \u2010 on ABC. Outcomes, adjusted for characteristics at drug start, were (i) incidence of overweight or obesity by 96\u2009weeks, (ii) zBMI change 48\u2009weeks before\/after drug start, (iii) association between TAF\/TDF\/ABC and anchor drug on zBMI change and (iv) factors associated with zBMI change on TAF over 96\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 162, 189, 270 and 144 were in groups 1, 2, 3 and 4, respectively. Median ages at drug start were 16, 13, 14 and 12\u2009years. Obesity incidence by 96\u2009weeks was 16%, 13%, 6% and 12% and higher on TAF than TDF (<jats:italic>p<\/jats:italic>\u2009=\u20090.018) but comparable to ABC (<jats:italic>p<\/jats:italic>\u2009=\u20090.568). Similar trends were seen for overweight\/obesity, although differences were not significant.<\/jats:p><jats:p>Over 48\u2009weeks, zBMI increased at a higher rate on TAF than TDF (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) but similar to ABC (<jats:italic>p<\/jats:italic>\u2009=\u20090.652). zBMI change was higher after than before drug start in group 1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.059) but similar in other groups.<\/jats:p><jats:p>Over 96\u2009weeks zBMI change on TAF\/TDF\/ABC combined with dolutegravir vs. other anchor drugs was not statistically different (<jats:italic>p<\/jats:italic>\u2009=\u20090.196). zBMI change on TAF varied by age (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), prior TDF (<jats:italic>p<\/jats:italic>\u2009=\u20090.019), viral load (<jats:italic>p<\/jats:italic>\u2009=\u20090.042) and zBMI (<jats:italic>p<\/jats:italic>\u2009=\u20090.004) at TAF start.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>zBMI increased on TAF, faster than TDF, but similar to ABC. Weight gain on TAF was associated with multiple factors including prior TDF use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.70070","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:00:22Z","timestamp":1754024422000},"page":"1418-1428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Weight gain on tenofovir alafenamide fumarate\u2010based therapy compared to tenofovir disoproxil fumarate\u2010 and abacavir\u2010based therapy in children and young people living with <scp>HIV<\/scp> in Europe"],"prefix":"10.1111","volume":"26","author":[{"name":"The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"World Health Organisation.Obesity and overweight. 2024.https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight. Accessed 07\/07\/2024"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003198"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703860"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000890"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003892"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00483-5"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016660812"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101412"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000833"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4853"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25702"},{"key":"e_1_2_12_13_1","volume-title":"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection","author":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV","year":"2024"},{"key":"e_1_2_12_14_1","unstructured":"Penta Foundation.Penta guidelines for first and second line antiretroviral treatment.2019."},{"key":"e_1_2_12_15_1","volume-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","author":"World Health Organization","year":"2021"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2404597"},{"key":"e_1_2_12_17_1","unstructured":"RakhmaninaN CunninghamK CottonMF et al.Weight gain analysis of HIV\u20101\u2010infected virologically suppressed participants age 6 to <18\u2009years who recieved a TAF\u2010containing regimen. International workshop on HIV pediatrics 2020. Virtual."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-023-04143-6"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003076"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.73.1.25"},{"key":"e_1_2_12_21_1","unstructured":"World Health Organization.WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV\u2010related disease in adults and children.2007."},{"key":"e_1_2_12_22_1","volume-title":"Growth Reference Data for 5\u201319\u2009Years","author":"World Health Organization","year":"2007"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab542"},{"key":"e_1_2_12_24_1","volume-title":"World Obesity Atlas 2024","author":"World Obesity Federation","year":"2024"},{"key":"e_1_2_12_25_1","volume-title":"Obesity Profile","author":"Office for Health Improvement and Disparities","year":"2023"},{"key":"e_1_2_12_26_1","unstructured":"Eurostat.Migrant integration statistics \u2010 at risk of poverty and social exclusion.2023."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1171"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2011.02.014"},{"key":"e_1_2_12_29_1","article-title":"Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. Journal of the international AIDS","volume":"25","author":"CIPHER","year":"2021","journal-title":"Society"},{"key":"e_1_2_12_30_1","volume-title":"A Simple Guide to Classifying Body Mass Index in Children","author":"Dinsdale H","year":"2011"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:45:28Z","timestamp":1756723528000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/hiv.70070"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70070","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"2025-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}